UNC School of Medicine researchers have led an international clinical trial of patients with generalized myasthenia gravis, ...

Autoimmune neuromuscular diseases may sound complex, but understanding them is the first step to getting the right care and ...

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

BridgeBio Pharma Inc.’s drug to treat a devastating muscle-wasting disorder met its goal in a late-stage trial, paving the ...

His parents Stephen and Jenny have asked Sheffield Children's NHS Foundation Trust to approve the use of drug givinostat, ...

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial. The ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially attacking ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Congenital muscular dystrophies (CMDs) comprise a heterogeneous group of inherited disorders primarily affecting muscle integrity and function, often with accompanying brain and ocular abnormalities.

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...